Olema Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

OLMA$7.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at March 31, 2024	55,867,863	$4	$572,926	$(10)	(336,602)	$236,318
Issuance of shares under at-the-market offering, net of issuance costs of $25	1,225,952	—	14,886	—	—	14,886
Stock-based compensation expense	—	—	5,542	—	—	5,542
Issuance of shares under the employee stock purchase plan	70,701	—	650	—	—	650
Employee stock purchase plan expense	—	—	182	—	—	182
Exercise of stock options	29,587	—	75	—	—	75
Vesting of restricted stock awards	52,308	—	—	—	—	—
Net unrealized loss on marketable securities	—	—	—	(108)	—	(108)
Net loss	—	—	—	—	(30,382)	(30,382)
Balances at June 30, 2024	57,246,411	$4	$594,261	$(118)	(366,984)	$227,163
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at December 31, 2023	54,992,784	$4	$559,176	$347	(305,632)	$253,895
Issuance of shares under at-the-market offering, net of issuance costs of $166	1,772,278	—	22,787	—	—	22,787
Stock-based compensation expense	—	—	10,246	—	—	10,246
Exercise of stock options	317,989	—	1,015	—	—	1,015
Issuance of shares under the employee stock purchase plan	70,701	—	650	—	—	650
Employee stock purchase plan expense	—	—	387	—	—	387
Vesting of restricted stock awards	92,659	—	—	—	—	—
Net unrealized loss on marketable securities	—	—	—	(465)	—	(465)
Net loss	—	—	—	—	(61,352)	(61,352)
Balances at June 30, 2024	57,246,411	$4	$594,261	$(118)	(366,984)	$227,163

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at March 31, 2023	40,438,320	$3	$413,213	$(978)	$(237,263)	$174,975
Stock-based compensation expense	—	—	4,040	—	—	4,040
Exercise of stock options	357,312	—	1,332	—	—	1,332
Issuance of shares under the employee stock purchase plan	270,541	—	711	—	—	711
Employee stock purchase plan expense	—	—	130	—	—	130
Vesting of early exercised stock options	6,990	—	30	—	—	30
Vesting of restricted stock awards	49,319	—	—	—	—	—
Net unrealized gain on marketable securities	—	—	—	460	—	460
Net loss	—	—	—	—	(20,095)	(20,095)
Balances at June 30, 2023	41,122,482	$3	$419,456	$(518)	(257,358)	$161,583
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at December 31, 2022	40,287,097	$3	$408,333	$(1,813)	$(208,977)	$197,546
Stock-based compensation expense	—	—	8,555	—	—	8,555
Exercise of stock options	452,227	—	1,552	—	—	1,552
Issuance of shares under the employee stock purchase plan	270,541	—	711	—	—	711
Employee stock purchase plan expense	—	—	245	—	—	245
Vesting of early exercised stock options	13,980	—	60	—	—	60
Vesting of restricted stock awards	98,637	—	—	—	—	—
Net unrealized gain on marketable securities	—	—	—	1,295	—	1,295
Net loss	—	—	—	—	(48,381)	(48,381)
Balances at June 30, 2023	41,122,482	$3	$419,456	$(518)	(257,358)	$161,583

Condensed Consolidated Statements of Cash Flows

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.